LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Mass Spectrometry Series Enhances Analytical Diagnostics

By LabMedica International staff writers
Posted on 12 Aug 2014
Print article
Image: The new Triple Quad 4500MD, along with the new QTRAP 4500MD, LC/MS/MS systems now provide analytic clinical diagnostics with flexibility, exceptional sensitivity, and faster data acquisition (Photo courtesy of AB SCIEX).
Image: The new Triple Quad 4500MD, along with the new QTRAP 4500MD, LC/MS/MS systems now provide analytic clinical diagnostics with flexibility, exceptional sensitivity, and faster data acquisition (Photo courtesy of AB SCIEX).
A leading mass spectrometry portfolio for analytic clinical testing has been expanded with a new series offering flexibility, exceptional sensitivity, and faster data acquisition.

SCIEX Diagnostics (Framingham, MA, USA), part of AB SCIEX, unveiled its latest products—theTriple Quad 4500MD and QTRAP 4500MD LC/MS/MS systems—at the American Association of Clinical Chemistry (AACC) Annual Meeting and Expo in Chicago, Illinois, July 29–31, 2014. Expected to be available in the US and select EU countries in September 2014, the 4500MD series joins the company's growing family of in vitro diagnostic devices, including the 3200MD and IVD-MS Analyzer systems launched in 2013, as well as a series of kits for vitamin D, immunosuppressants, and newborn screening testing to be available in August 2014 for use in certain European countries.

The new 4500MD series offers exceptional sensitivity and faster data acquisition over previous systems, providing reliable results so physicians and patients have accurate answers quickly. It is a flexible LC/MS/MS platform that offers enhanced performance to enable customers developing their own applications to validate methods that require lower detection limits or higher throughput, with the peace of mind afforded by a regulatory compliant solution.

"As scientific understanding progressively evolves into improved clinical diagnostic testing, diagnostic customers who develop their own assays are turning to fast, sensitive instruments to perform routine tests with high efficiency and cost savings," said Chris Radloff, vice president of Applied Markets and Clinical Research at AB SCIEX, "By bringing the power, flexibility, reliability, and accuracy of our mass spectrometry technology to clinical testing laboratories, AB SCIEX is enabling customers to deliver high quality diagnostic information to clinicians who make decisions affecting patient care."

Related Links:

SCIEX Diagnostics
AB SCIEX

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more